Trial · NCT07894978
Expand Your Horizon-Spanish
NCT07894978, Not applicable, Not yet recruiting, Universitat Autonoma de Barcelona
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Expand Your Horizon-Spanish. Trials, record NCT07894978. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894978
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Expand Your Horizon-Spanish
- NCT number
- NCT07894978
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 200 participants, estimated
- Lead sponsor
- Universitat Autonoma de Barcelona
- Conditions
- Body Image, Body Image Dissatisfaction, Eating Disorders, University Students, Prevention
- Interventions
- Expand Your Horizon (EYH), Creative Writing Control
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Functionality Appreciation (Functionality Appreciation Scale (FAS)) | Baseline (day 1), immediately post-intervention (day 7), and 1-month follow-up. | Functionality appreciation will be assessed using the 7-item Functionality Appreciation Scale (FAS), which measures appreciation of the body for what it can do and is capable of doing. Items are rated on a 5-point scale from 1 (strongly disagree) to 5 (strongly agree). The mean item score ranges from 1 to 5, with higher scores indicating greater appreciation of body functionality. |
| Primary | Body Appreciation (Body Appreciation Scale-2 (BAS-2)) | Baseline (day 1), immediately post-intervention (day 7), and 1-month follow-up. | Body appreciation will be assessed using the 10-item Body Appreciation Scale-2 (BAS-2), which measures body acceptance, respect for and care of one's body, and protection from unrealistic beauty standards. Items are rated on a 5-point scale from 1 (never) to 5 (always). The mean item score ranges from 1 to 5, with higher scores indicating greater body appreciation. |
| Secondary | Body Image Flexibility (Body Image Acceptance and Action Questionnaire-5 (BI-AAQ-5)) | Baseline (day 1), immediately post-intervention (day 7), and 1-month follow-up. | Body image flexibility will be assessed using the 5-item Body Image Acceptance and Action Questionnaire-5 (BI-AAQ-5). Items are rated on a 7-point scale from 1 (never true) to 7 (always true). Items are reverse-coded and averaged to yield a mean score ranging from 1 to 7, with higher scores indicating greater body image flexibility. |
| Secondary | Self-Compassion (Self-Compassion Scale-Short Form (SCS-SF)) | Baseline (day 1), immediately post-intervention (day 7), and 1-month follow-up. | Self-compassion will be assessed using the 12-item Self-Compassion Scale-Short Form (SCS-SF). Items are rated on a 5-point scale from 1 (almost never) to 5 (almost always). The mean item score ranges from 1 to 5, with higher scores indicating greater self-compassion. |
| Secondary | Eating Disorder Symptoms (Eating Disorder Examination Questionnaire (EDE-Q-7)) | Baseline (day 1), immediately post-intervention (day 7), and 1-month follow-up. | Eating disorder symptoms will be assessed using the 7-item Eating Disorder Examination Questionnaire (EDE-Q-7), which measures core aspects of eating disorder psychopathology, including dietary restraint, overvaluation of shape and weight, and body dissatisfaction. Items are rated on a 7-point scale from 0 (no days/not at all) to 6 (every day/markedly). Items are averaged to yield a total score, with higher scores indicating greater eating disorder symptomatology. |
| Secondary | Mentalization (Reflective Functioning Questionnaire (RFQ-8)) | Baseline (day 1), immediately post-intervention (day 7), and 1-month follow-up. | Mentalization will be assessed using the 8-item Reflective Functioning Questionnaire (RFQ-8). Items are rated on a 7-point Likert scale from 1 (strongly disagree) to 7 (strongly agree). Items are reverse-coded and averaged to yield a total score, with higher scores indicating greater mentalizing capacity. The Spanish version has demonstrated good psychometric properties and supports a unidimensional structure and the use of a single overall score (Cronbach's α = 0.76). |
| Other | Intervention Adherence | Immediately post-intervention (day 7) | Adherence to the writing program will be assessed using automated Qualtrics platform usage data. Adherence will be measured by the number of writing exercises completed (range: 0-3) and the proportion of participants completing all three exercises. Time spent on each exercise will also be recorded. |
| Other | Participant Satisfaction with EYH | Immediately post-intervention (day 7) | Satisfaction with the EYH intervention will be assessed among participants in the intervention group at post-intervention using four adapted items from the Client Satisfaction Questionnaire (CSQ-8). Items assess satisfaction with the program, perceived quality, willingness to repeat the program, and willingness to recommend it to others. Items are rated on a 4-point scale. Participants will also answer three open-ended questions about perceived benefits and whether the program changed how they think about or relate to their bodies. |
| Other | Qualitative Themes in EYH Writing Responses | Intervention day 1, intervention day 2, intervention day 3 | Written responses to the three EYH exercises will be analyzed qualitatively to explore how participants describe and make sense of their bodies and body functionality. The analysis will examine themes in participants' accounts and consider shared and context-specific patterns across Spain and Argentina. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers11
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894978
GET https://conductscience.org/api/trials/v1/NCT07894978/registered